Announcements

Olema Pharmaceuticals, Inc. filed a current report on Form 8-K on August 13, 2026, disclosing the appointment of Jason O'Byrne as Chief Financial Officer, principal financial officer, and principal accounting officer, effective August 11, 2026.

Sagimet Biosciences Inc. filed a Form 8-K on August 13, 2026, reporting that the U.S. Food and Drug Administration cleared the company's Investigational New Drug application and issued a "Study May Proceed" letter for a Phase 3 clinical trial of denifanstat in moderate to …

Rocket Lab Corporation filed a Form 8-K on August 13, 2026, disclosing the entry into an Equity Distribution Agreement with Deutsche Bank Securities Inc. and Wells Fargo Securities, LLC to sell up to $1,944,369,826 of common stock through an at-the-market program, and separately announced …

Fermi Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on August 13, 2026, announcing its financial results for the second quarter ended June 30, 2026, and furnishing an earnings release and investor presentation as exhibits.

Wabash National Corporation filed an 8-K on August 13, 2026, disclosing that on August 12, 2026, it entered into a Sixth Amendment to its Second Amended and Restated Credit Agreement, establishing a $300 million revolving credit facility maturing as early as August 12, 2031.

Collegium Pharmaceutical, Inc. filed a Form 8-K on August 13, 2026, disclosing the execution of a $50 million accelerated share repurchase agreement with Jefferies LLC as part of a broader $150 million board-authorized buyback program.

Intuitive Machines, Inc. filed a Form 8-K with the SEC on August 13, 2026, reporting its financial results for the fiscal quarter ended June 30, 2026, and disclosing a quarter-end backlog of $1.8 billion according to the accompanying press release.